<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257725</url>
  </required_header>
  <id_info>
    <org_study_id>4939</org_study_id>
    <nct_id>NCT00257725</nct_id>
  </id_info>
  <brief_title>Long-Duration Stimulant Treatment Study of ADHD in Young Children</brief_title>
  <acronym>B-MPH</acronym>
  <official_title>Long-Duration Stimulant Treatment of ADHD in Young Children-Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if Ritalin LA™ is safe and effective for ADHD treatment in&#xD;
      4-to-5-year olds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single site, open-label, four-week feasibility study of long-duration beaded&#xD;
      methylphenidate (B-MPH), also known as Ritalin LA™. B-MPH is a FDA-approved medication for&#xD;
      children 6 years and older with attention-deficit/hyperactivity disorder (ADHD), but there&#xD;
      are no studies of its use in preschoolers. This study will evaluate the safety and&#xD;
      effectiveness of B-MPH for ADHD treatment in 4-to-5-year old children.&#xD;
&#xD;
      Total study duration is approximately 5 weeks. It includes a screening evaluation and 4 weeks&#xD;
      of B-MPH treatment with doses ranging from 10 to 30 mg (based on the individual tolerability&#xD;
      and efficacy). The study doctor will conduct parent-training sessions during the treatment&#xD;
      visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)</measure>
    <time_frame>week 5</time_frame>
    <description>The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.&#xD;
Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions-Severity (CGI-S)</measure>
    <time_frame>week 5</time_frame>
    <description>CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.&#xD;
Range: 0-7, higher score means worse outcome. Change from baseline is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Global Assessment Scale (C-GAS)</measure>
    <time_frame>week 5</time_frame>
    <description>Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>ADHD Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-MPH</intervention_name>
    <description>Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days</description>
    <arm_group_label>ADHD Treatment Group</arm_group_label>
    <other_name>Ritalin LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Parents/guardians and children must speak English and/or Spanish; parents/guardians&#xD;
             must sign consent form; children must verbally assent.&#xD;
&#xD;
          2. Boys and girls from 4-5 years old (inclusive) at screening.&#xD;
&#xD;
          3. Children who meet the DSM-IV criteria for a primary diagnosis of ADHD (combined or&#xD;
             hyperactive subtype), with symptoms present for at least 9 months.&#xD;
&#xD;
          4. Children who demonstrate adequate need for treatment due to ADHD symptom-severity and&#xD;
             clinical impairment.&#xD;
&#xD;
          5. Children with IQ of at least 70 confirmed by valid IQ test.&#xD;
&#xD;
          6. Children who are in educational settings (pre-school, kindergarten, or elementary&#xD;
             school program) with at least 8 same-age peers for at least two half days weekly.&#xD;
&#xD;
          7. Parents and children who can attend weekly study visits.&#xD;
&#xD;
          8. Children who are naïve to ADHD medications; received ADHD medications in the past but&#xD;
             are not currently treated; or on ADHD medications but finding them inconvenient (due&#xD;
             to short duration of action) or not very helpful&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children and parents/guardians who do not understand or cannot follow necessary&#xD;
             instructions; children and parents who are unwilling to comply with study procedures&#xD;
             or cooperate with child psychiatrist.&#xD;
&#xD;
          2. Children taking excluded medications.&#xD;
&#xD;
          3. Children with history of intolerance to MPH/stimulant medications or no response to&#xD;
             adequate stimulant trials.&#xD;
&#xD;
          4. Children with current adjustment disorder, autism, psychosis, bipolar disorder,&#xD;
             significant suicidality, or other psychiatric disorders.&#xD;
&#xD;
          5. Children with history of physical, sexual, or emotional abuse, which lead to a&#xD;
             significant impact on the clinical presentation and potentially some ADHD symptoms.&#xD;
&#xD;
          6. Children with screening abnormalities deemed clinically significant by child&#xD;
             psychiatrist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence L Greenhill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Insitute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Insitute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Maayan L, Paykina N, Fried J, Strauss T, Gugga SS, Greenhill L. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. J Child Adolesc Psychopharmacol. 2009 Apr;19(2):147-53.</citation>
    <PMID>19374023</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 21, 2005</study_first_submitted>
  <study_first_submitted_qc>November 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2005</study_first_posted>
  <results_first_submitted>December 17, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Laurence Greenhill</investigator_full_name>
    <investigator_title>Research Psychiatrist 2</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Attention-deficit/hyperactivity disorder (ADHD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through the NYSPI Child and Adolescent Evaluation Service (CAPES), physician referrals, local and web advertising, and flyers. Recruitment took place between March 2005 and August 2007</recruitment_details>
      <pre_assignment_details>The study included screening and one-week washout (if needed). All participants were entered into the study without incident.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ADHD Treatment Group</title>
          <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single-arm Open-label B-MPH Treatment in Preschoolers w ADHD</title>
          <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)</title>
        <description>The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.&#xD;
Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported.</description>
        <time_frame>week 5</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>ADHD Treatment Group</title>
            <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD</description>
          </group>
        </group_list>
        <measure>
          <title>Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)</title>
          <description>The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.&#xD;
Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported.</description>
          <population>Intent to treat (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impressions-Severity (CGI-S)</title>
        <description>CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.&#xD;
Range: 0-7, higher score means worse outcome. Change from baseline is reported.</description>
        <time_frame>week 5</time_frame>
        <population>intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>ADHD Treatment Group</title>
            <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions-Severity (CGI-S)</title>
          <description>CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.&#xD;
Range: 0-7, higher score means worse outcome. Change from baseline is reported.</description>
          <population>intent to treat (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Children's Global Assessment Scale (C-GAS)</title>
        <description>Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported.</description>
        <time_frame>week 5</time_frame>
        <population>intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>ADHD Treatment Group</title>
            <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
          </group>
        </group_list>
        <measure>
          <title>Children's Global Assessment Scale (C-GAS)</title>
          <description>Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported.</description>
          <population>intent to treat (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks (Baseline and 4 treatment visits)</time_frame>
      <desc>Using open-ended questions, the child psychiatrist elicited information about adverse events at baseline and at each subsequent visit. Information was obtained by observation and direct questioning such as, &quot;Have you had any (other) medical problems since your last visit?&quot; or &quot;Have you felt different in any way since your last visit?&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Single-arm Open-label B-MPH Treatment in Preschoolers w ADHD</title>
          <description>Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Virus with fever and headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye Redness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble Sleeping</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased Sensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye Twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Emotional Lability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The conclusions of this study are limited by its small size, the open-label design, and the possible confound of the parent training intervention.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Laurence Greenhill, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>212-543-5340</phone>
      <email>GREENHIL@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

